Clinical trials: Telephone 0207 0343341

Clinical trials specialists in the heart of London

Copyright © Heart Lung Centre Site Made With ♥️ By Gossh Expert 2xN

You can have a role in research that could change medicine forever.

Paid clinical research studies are being conducted at Heart Lung Centre to learn more about investigational medications that are not yet available to the public.

Are Clinical Trials safe?

This is a very important question. At Heart Lung Centre, all our trials are reviewed by an independent Research Ethics Committee, who ensure that our trials are as safe as possible. We are here to answer any questions.

 

Learn More

Do I get paid?

Our trials vary greatly in terms of time spent on the unit and the number of procedures performed. Once we have identified a suitable trial, we can inform you of the potential compensation for your participation.

 

Learn More

What facilities are there?

Whether you’re here for an hour or the whole day, we will endeavour to make your stay as comfortable as possible. The volunteer lounge will provide you with a space to pass the time pleasantly between assessments.

 

Why do you offer Clinical Trials?

Here at Heart Lung Centre we adhere to MHRA (The Medicines and Healthcare products Regulatory Agency) who are responsible for regulating the UK medical devices market. You can find out more information here.

VOLUNTEER REGISTRATION FORM 

Explore current trials to check eligibility and register

We do not have any studies for healthy volunteers.

  • Asthma Studies

    Asthma Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of asthma.

    To take part in our studies you:

    • Must have been diagnosed with Asthma for 12 months or more
    • Must not be, pregnant, lactating or trying to conceive with your partner (if applicable)
    • Must not be currently enrolled in another clinical trial

    For all studies, participants are reimbursed for their time, travel and inconvenience. If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    Current studies are detailed below.

  • Chiesi – BETRI

    This is a Phase 4, randomised, open-label clinical study to compare the efficacy and safety of the inhalers, Trimbow vs Foster in asthma subjects. Trimbow is a triple acting inhaler containing beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in the dosage 87/5/9mcg. Whilst Foster is a dual acting inhaler containing beclometasone dipropionate/formoterol fumarate in the dosage 200/6mcg.

    Both these products have gone through their developmental lifestyle and have been approved for treatment of asthma and COPD. They are part of the asthma expert guidelines and are used widely for asthma. Overall, the risks are minimal since these inhalers are marketed products and their safety profile is documented in the Summary of Product Characteristics, which is readily accessible online.

    Your participation in this study will last approximately 12 months and will include 7 visits: 3 onsite visits and 4 videocalls. The onsite visits will occur every 6 months and will last approximately 30–90 minutes each. The videocalls will occur every 2 months and will last approximately 10–15 minutes each. During these calls, study staff will confirm that you have received your study medication, which will be shipped directly to your home by courier.

    To assess your eligibility, the screening visit will include questions about your medical history, physical assessment and vital signs, and might include blood tests, urine test and lung function testing if needed. If you are found to be eligible, you will be enrolled into the study and where you will be randomly assigned to take either Trimbow or Foster 2 puffs in the morning and two puffs in the evening for 12 months and will be required to download an app to complete short questionnaires throughout the study. You must also stop taking your current inhaler, but you will be free to use salbutamol as needed throughout the study.

    For your time and inconvenience, you will be reimbursed £13.50 per visit, totalling up to £94.50.

    Optional: At the first visit you will be asked if you would like the Concierge Service (CS) to help facilitate your participation in the study. This involves someone reaching out from the CS team via telephone and/or email to remind you to complete questionnaires.

    Note: This is an optional service which you do not have to consent to, to be part of the study.

    To take part in this study, you:

    • Must have a diagnosis of asthma of at least 1 year
    • Must be above the age of 18
    • Must be on preventative (non-blue) inhaler for at least 3 months
    • Must have had oral steroids or visited the hospital for an asthma flare-up in the last 12 months

    If you’re interested and would like to find out if you’re eligible, please register your interest at /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or email us at recruitment@heartlungcentre.com.

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

  • COPD studies​

    Chronic Obstructive Pulmonary Disease Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of COPD.

    To take part in our studies you:

    • Must not be, pregnant, lactating or trying to conceive with your partner (if applicable)
    • Must not be currently enrolled in another clinical trial

     

    For all studies, participants are reimbursed for their time, travel and inconvenience. If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    Current studies are detailed below.

  • COPD Study: Oratos

    This study is a randomised, double-blinded, placebo-controlled crossover study to assess the effect of Trixeo inhaler versus placebo on cardiac and lung function in participants with COPD and hyperinflation.

    This triple-acting inhaler contains Budesonide/Glycopyrronium/Formoterol Fumarate and is currently approved for the treatment of COPD in several countries. 5 phase III studies have indicated that this inhaler is safe and well tolerated.

    In total, there will be 6 visits over 11 weeks, with visits every 2-3 weeks. You will receive both the placebo inhaler and study drug in separate 3-week treatment periods, where you will take the medication 2 puffs twice a day, in the morning and evening. Additionally, all maintenance inhalers would need to be stopped throughout the study duration, but you will be free to use Salbutamol as needed. If you are on a prescribed LAMA inhaler, an additional SAMA, ipratropium bromide will be dispensed for use as needed.

    At the screening visit, we will assess your eligibility by asking questions about your medical history, a physical assessment, vital signs, ECG, blood tests and lung function testing. If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests and vital signs, and will be issued and taught how to use your e-dairy.

    During the trial, you will undergo three cardiac MRIs and three Echocardiograms with Medneo, our medical imaging partner based in Central London. Questions/ concerns can be discussed in person with our medical team. An MRI is a medical imaging technique that uses magnetic fields and radio waves to create detailed images of the inside of your body. Whilst an Echocardiogram is an ultrasound scan to look at your heart and nearby blood vessels.

    For your time and inconvenience, you will be reimbursed £80 on your first visit. If you are found to be suitable and are enrolled into the study, you will be reimbursed up to £880. Your travel will also be reimbursed up to £100.

    To take part in this study you:

    • Must have a diagnosis of COPD.
    • Must be aged between 40 and 80.
    • Must use a daily preventative inhaler (non-blue inhaler) for at least 6 weeks.
    • Must be a current or ex-smoker.

     

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Other Studies

    In addition to our asthma and COPD studies, we are also conducting research into potential new therapies for other conditions.

    If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    Current studies are detailed below.

  • None available at present

FAQ'S

If you want to know more about clinical trials or are considering participating in one, the following frequently asked questions describe the role of a patient and will help you understand this unique research program.

FAQ'S

Location

Explore beyond the Heart Lung Centre and discover Respiratory Clinical Trials and our hospital Queen Anne Street Medical Centre. Our state of the art facility offers a range of medical services, including consultants in different specialties, diagnostic tests and an operating theatre.

13-14 Fitzroy Square,
London, W1T 6AH

E: recruitment@heartlungcentre.com
P: 0207 0343341

Give us a call or email us, we endeavour to answer all enquiries within 24 hours on business days.

We are open from 8am — 5pm week days.